Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients

OBJECTIVE: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor fluorescence in situ hybridization (FISH). It has been used successfully in the USA following its Food and Drug Administration approval in 2001. However, the technology was not approved for use in Japan until 2017. C...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Asian Pac J Cancer Prev
Hlavní autoři: Nagai, Takashi, Okamura, Takehiko, Yanase, Takahiro, Chaya, Ryosuke, Moritoki, Yoshinobu, Kobayashi, Daichi, Akita, Hidetoshi, Yasui, Takahiro
Médium: Artigo
Jazyk:Inglês
Vydáno: West Asia Organization for Cancer Prevention 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948889/
https://ncbi.nlm.nih.gov/pubmed/31030505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31557/APJCP.2019.20.4.1271
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky